Christian Hansen

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

Profound Pharma AS provides pharmaceutical products. The Danish company was founded by Jan Møller Mikkelsen, Anders H. Pedersen, Hans Thalsgård Schambye. Profound Pharma was acquired by Maxygen, Inc. on August 10, 2000 for $69.46 million.

Nordic Biotech Advisors ApS (NB Capital) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2001 by Florian Schönharting and Dr. Christian Hansen, and is owned by a group of institutional investors.

Rose Pharma A/S provides pharmaceutical products for treatment of pain in connection with irritable bowel syndrome. It develops treatments for irritable bowel syndrome (IBS) and functional dyspepsia, and disorders. The firm focuses on the medical applications of gastrointestinal hormones. The company was founded in 2003 and is headquartered in Roskilde, Denmark.

Osteologix Holdings Plc engaged in the development of innovative pharmaceuticals for the treatment and prevention of bone and joint tissues diseases. The company was founded in October 2004 and was headquartered in Dublin, Ireland.

Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 2005 and is headquartered in Copenhagen, Denmark.

Blue Note Pharmaceuticals is a privately held biopharmaceutical company with offices in Troy, New York and Amsterdam, The Netherlands. Blue Note's mission is to acquire, advance, develop, partner and commercialize carefully selected undervalued drug development candidates with the potential to more effectively treat or help prevent major medical conditions affecting society. The Company's lead development project is BNP 32,762, a pharmacokinetically unique calcium channel blocker (CCB) being evaluated in late-stage clinical trials for the treatment of hypertension and chronic stable angina. Blue Note is also evaluating various products that would combine BNP 32,762 with other commonly accepted antihypertensive drugs such as ACE inhibitors, Angiotensin Receptor Blockers (ARBs) and diuretics. The Company's cardiovascular-oriented pipeline also includes an early-stage program for the prevention of Deep Vein Thrombosis (DVT) and for the treatment of a number of other important cardiovascular indications.